Vargatef®
Combination therapy with docetaxel for the treatment of adult patients with locally advanced, metastatic or locally non-small cell lung cancer (NSCLC) of adenocarcinoma tumour histology after first-line chemotherapy.
Search
Introduction to head-to-head trials
Hear from experts Dr Kerr and Dr Melosky.
Zongertinib (BI 1810631)
Zongertinib (BI 1810631)
Avian influenza prevention at the source
Teshome Mebatsion, Head of Viral Diseases Research at Boehringer Ingelheim, talks about the avian influenza virus, ways of prevention and scenarios for the future.
Avian influenza 5 things you should know
Communities across the globe are faced with outbreaks of bird flu. We stand with poultry farmers and veterinarians and supports the effort against the disease
The liver and its vital connection to our overall health
How health of the liver impacts our interconnected cardiovascular, renal, metabolic system and suffering and can have several comorbidities like obesity.
Elke
People with Type 2 diabetes (T2D) have an increased risk of heart disease.
Our Innovation Strategy
A deep understanding of disease, identifying relevant mechanisms and choosing therapeutic modalities to address them is the core of our innovation strategy
Giotrif®
For the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumours have activating epidermal growth factor receptor (EGFR) mutations. For the treatment of patients with locally advanced or metastatic NSCLC of squamous hist
Professor Baumgart
Information for people with type 2 diabetes (T2D) on why it is important to consider their heart and suggested measures that can be taken to reduce the risk of heart disease
BI 764532
DLL3/CD3 T-cell engager
Biotherapeutics Discovery
We are applying our deep understanding of disease biology to design a diverse range of novel modalities that are the foundation for life-changing biotherapeutics for patients.
Breakthrough-Therapy-Designation-Progressive-Fibrosing-ILD
FDA Grants nintedanib Breakthrough Therapy Designation for Chronic Fibrosing ILDs with a Progressive Phenotype
ATM-Ranking-2021
Boehringer Ingelheim climbs two places. New early-stage research projects for disease areas relevant to low-to-middle income countries not reflected.
Reinhold
People with type 2 diabetes have an increased risk of heart disease and this can have a profound impact on their everyday lives
Taking Cancer on at Diagnosis
We spoke to Markus, Brigitte and Dr Hochmair who shared their advice for people starting their own cancer journeys.
Liu
Hear Liu share his experience of being diagnosed with type 2 diabetes and heart disease on the same day and the impact this simultaneous diagnosis has had on his life as he knew it.
Isabel
In this video, Isabel shares how watching her children and grandchildren grow up inspires her to take the necessary steps to manage her life with type 2 diabetes and heart disease.
Boehringer Ingelheim opens Health Management Centre in China
Boehringer Ingelheim opens Health Management Centre in China The new Health Management Centre integrates animal disease and health diagnostics as well as monitoring tools The centre further strengthens the company’s ability to provide services along the f
DCRI-collaboration-empact-mi
Collaboration with Duke Clinical Research Institute on EMPACT-MI trial, which will assess outcomes in people who have had a myocardial infarction
Nerandomilast (BI 1015550)
Nerandomilast (BI 1015550): PDE4B inhibitor
Facts About Asthma
Understand more about what asthma is, how asthma is diagnosed and what you can do to reduce symptoms in your day to day life.
Nerandomilast (BI 1015550)
Nerandomilast (BI 1015550): PDE4B inhibitor
Genomic Lens Linking Worlds in DNA
Adding a new dimension to drug discovery with the help of data science and DNA
Over 100 billion birds vaccinated with VAXXITEK
Boehringer Ingelheim celebrates that over 100 billion birds have been vaccinated with VAXXITEK® HVT + IBD in October 2018.